View ValuationImagion Biosystems 将来の成長Future 基準チェック /06現在、 Imagion Biosystemsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長16.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 02Imagion Biosystems Ind Application for Magsense Phase 2 Clinical Trial Clears Fda ReviewImagion Biosystems Ltd. announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND) application, issuing a “Study May Proceed” letter for Phase 1b/2 clinical trials of the MagSense Imaging Agent in HER2+ breast cancer. MagSense is a first-of-its-class molecular MRI (mMRI) imaging agent that uses non-radioactive, bio-safe nanoparticles to help clinicians detect cancer earlier and with greater precision. Phase 1b/2 will be a combined trial designed to confirm the safety profile (Phase 1b) and evaluate efficacy in detecting nodal metastases (Phase 2) in patients with HER2+ breast cancer. Dr. Mohammad Eghtedari, section chief of Women's Imaging at City of Hope Cancer Center in Los Angeles, will serve as the trial’s principal investigator (PI). Eghtedari previously participated as an independent reviewer of MagSense in the company’s Phase I trial. The company expects the trial to yield insights into the potential impact on cost of care, patient outcomes, and clinical value. Paired with quantitative imaging techniques, the trial may produce critical training data for AI diagnostic tools. Conventional imaging can identify regions of interest using anatomical or morphological features, but without molecular specificity, cannot reliably differentiate benign from malignant tumors. MagSense uses targeted nanoparticles to increase imaging specificity, making it easier for clinicians to make diagnoses with certainty. The platform technology’s applications extend beyond breast cancer—Imagion has conducted pre-clinical studies of two additional imaging agents that target prostate and ovarian cancers, which will be prepared for IND-enabling studies.お知らせ • Apr 07Imagion Biosystems Limited, Annual General Meeting, May 26, 2026Imagion Biosystems Limited, Annual General Meeting, May 26, 2026.お知らせ • Feb 04Imagion Biosystems Ltd. Lodges IND with FDA for Phase 2 Trial of MagSense HER2 Targeting Imaging AgentImagion Biosystems Ltd. announced that the company has progressed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its MagSense®? targeted imaging agent. Following FDA approval, the company expects to start a Phase 2 clinical trial with the imaging agent for the detection of nodal metastases in HER2+ breast cancer patients. MagSense®? is a first-of-its-class molecular MRI (mMRI) platform technology that uses iron oxide nanoparticles with custom moieties (e.g., antibodies) to target specific disease biomarkers. Unlike general purpose contrast agents, MagSense®? particles are only detected when and where cancer is present. Using MRI, the presence of iron oxide produces a significant, identifiable change in image contrast, empowering clinicians with better information for diagnosis and treatment planning. Based on historical FDA review timelines, the company anticipates enrollment for the Phase 2 trial could begin as early as first quarter 2026. The company has selected and engaged all required strategic trial partners to manage the study and has begun the process of clinical study site engagement and progressing study logistics in compliance with Good Clinical Practices.お知らせ • Sep 01Imagion Biosystems Limited Appoints Nina Webster as Non- Executive Director, Effective 1 September 2025Imagion Biosystems Limited announced the appointment of Dr. Nina Webster as a Non-Executive Director to the Board, effective 1 September 2025. Dr. Webster brings to the Board a wealth of experience in the Australian ASX listed pharmaceutical industry, holding leadership roles over a thirty-year period. She currently serves as Managing Director and Chief Executive Officer of Dimerix Ltd. Formerly the Commercial Director for Acrux Limited and Director of Commercialisation and Intellectual Property for Immuron Limited, Nina brings to IBX vast experience in investor relations, strategic planning, and scientific and operational execution. Dr. Webster holds a Ph.D in Pharmaceutics, a Bachelor's degree in Pharmacology, a Master's degree in Intellectual Property Law and an Executive MBA and currently also serves as Non-Executive Chairperson for SYNthesis BioVentures and as Non-Executive Director for Linear Clinical Research Limited. The addition of Dr. Webster to the IBX Board of Directors will further strengthen the Board's capabilities as the Company continues to execute on its strategic objectives to develop and gain regulatory approval for its pipeline of MagSense® molecular imaging technologies.お知らせ • Aug 04Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 223,333,333 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Apr 01Imagion Biosystems Limited, Annual General Meeting, May 30, 2025Imagion Biosystems Limited, Annual General Meeting, May 30, 2025.お知らせ • Dec 13Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million.Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Nov 08Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 0.125 million.Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 0.125 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Aug 01Imagion Biosystems Limited Announces Board ChangesImagion Biosystems Limited announced that Ms Melanie Leydin will join the Board as a Non-Executive Director with the appointment effective from 31 July 2024. Ms Leydin has over 25 years' experience in the accounting profession and over 15 years as a company secretary with extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, re-organization of Companies and shareholder relations. IBX announced that, effective immediately before the conclusion of the General Meeting scheduled on 22 August 2024, Michael Harsh, David Ludvigson and Mark Van Astan, will cease to hold office. (That is, all of the directors who were in office at the time the directors' report (as included in the Company's annual financial report for the financial year ended 31 December 2023) was approved, other than Robert Proulx who acts as Executive Chairman and Managing Director, will cease to hold office).お知らせ • May 06Imagion Biosystems Limited, Annual General Meeting, May 31, 2024Imagion Biosystems Limited, Annual General Meeting, May 31, 2024, at 10:01 E. Australia Standard Time. Location: K&L Gates Melbourne, Level 25, 525 Collins Street Melbourne Victoria Australia Agenda: To receive and consider the Financial Report of the Company and its controlled entities and the related Directors' and Auditor's Reports in respect of the financial year ended 31 December 2023; to consider adoption of the Remuneration Report; to approve re-Election of Director; and to consider other matters.お知らせ • Jan 15+ 1 more updateImagion Biosystems Limited Announces Departure of Isaac Bright as CEOImagion Biosystems Limited informed the market that CEO, MD has resigned to pursue other opportunities effective January 15th, 2024.お知らせ • Nov 15Imagion Biosystems Limited Approves Election of Isaac Bright as DirectorImagion Biosystems Limited announced that at its Extraordinary General Meeting held on 13 November 2023, the shareholders approved Election of Director - Dr. Isaac Bright.お知らせ • Jul 17+ 1 more updateImagion Biosystems Limited Appoints Robert Proulx as Non-Executive ChairmanImagion Biosystems Limited announced that Robert Proulx is transitioning from his roles as President and CEO, and will be staying on as Non-Executive Chairman of the Board. This completes the leadership restructuring plan announced on 28 April 2023, which initiated the process to separate the role of the Chair from the role of CEO. To effect his transition to Non-Executive Chairman, the Company and Mr. Proulx by way of mutual consent ceased Mr. Proulx's employment under his previous roles, effective 20 June 2023. Mr. Proulx is assisting the incoming CEO, Dr Isaac Bright, from 20 June 2023 to 31 July 2023 to allow for a streamlined transition period for the Company. During this handover period (finishing on 31 July 2023), Mr. Proulx will receive a total payment commensurate to 60% of the base salary as specified in his most recent employment agreement (and as outlined in the annexure to this announcement). From 1 August 2023 Mr. Proulx will revert to a Chairman's fee of $63,000 per annum. Mr. Proulx commenced as Non-Executive Chairman on 20 June 2023. The key terms of his From the period of 20 June 2023 to 31 July 2023, Mr. Proulx will be paid at a rate of 60% of his base annual salary as specified in his most recent employment agreement (which equates to an annualized salary of $192,000 being 60% of $320,000). Mr. Proulx's appointment as Non-Executive Chairman of the Board may be terminated at any me in accordance with the provisions of the Company Constitution or the provisions of any applicable law. On any termination, no fee will be payable to Mr. Proulx in respect of any unexpired on of the term of his appointment.お知らせ • Jun 19Imagion Biosystems Limited Announces CEO ChangesImagion Biosystems Limited announced it has appointed Isaac Bright, MD as CEO, effective 20 June 2023. Dr. Bright is a results-focused business leader and brings to Imagion over 20 years of experience as a health industry executive and venture capitalist in medical technology, biopharmaceuticals, and oncology-based molecular diagnostics. Dr. Bright most recently served as Co-Founder, CEO, and Chairman of RubrYc Therapeutics Inc. before its trade sale to iBio Inc. in September 2022. Prior to launching RubrYc, Dr. Bright was Chief Business Officer for molecular diagnostics innovator HealthTell Inc., driving its trade sale to iCarbonX, concomitant with RubrYc’s launch in 2018. Prior to that, Dr. Bright served as VP, Corporate Development for Synthetic Biologics Inc. and consulting Chief Business Officer for synthetic biology innovator musebio Inc. (currently Incripta Inc.) as it secured its $23 million Series B Preferred financing. Dr. Bright was the first American Partner investing with Merieux Developpement (currently, Merieux Equity Partners) from 2012 through 2016, during which he helped the firm raise €150 million Merieux Participations 2 fund. With Merieux, Dr. Bright led investments and Board representation for Imaginab Inc., Kalila Medical Inc. until its acquisition by Abbott, and Twist Bioscience before its IPO. Dr. Bright’s startup experience began as he built and led QuantaLife Inc.’s Corporate Development and Molecular Diagnostics functions from 2009-2011, leading to QuantaLife’s acquisition by Bio-Rad Laboratories Inc. Previously, Dr. Bright served as Sr. Associate, Corporate Development and Director, Business Development - Neuromodulation for global medtech leader Medtronic. Dr. Bright earned his bachelor’s degree in biochemistry from Pepperdine University, his medical degree from the Stanford University School of Medicine and was a Howard E. Mitchell Fellow earning his MBA from the Wharton School at the University of Pennsylvania. The hiring of Dr. Bright follows from the recent announcement on 28 April 2023 regarding the plan for Bob Proulx to retire from the role of CEO, remaining as Chairman of the Board. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Imagion Biosystems は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:IBXX.F - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20250-4-4-4N/A9/30/20251-3-3-3N/A6/30/20251-2-3-3N/A3/31/20252-2-2-2N/A12/31/20243-2-1-1N/A9/30/20244-4-2-2N/A6/30/20246-6-3-2N/A3/31/20245-9-6-5N/A12/31/20235-12-9-8N/A9/30/20234-12-9-9N/A6/30/20233-12-10-9N/A3/31/20233-11-9-9N/A12/31/20223-10-9-8N/A9/30/20222-10-9-9N/A6/30/20220-10-10-9N/A3/31/20222-8-7-7N/A12/31/20213-6-5-5N/A9/30/20213-6-5-5N/A6/30/20213-5-4-4N/A3/31/20213-5-4-4N/A12/31/20203-5-5-5N/A9/30/20203-5-4-4N/A6/30/20202-4-2-2N/A3/31/20202-4-3-3N/A12/31/20192-3-4-4N/A9/30/20192-4N/A-5N/A6/30/20192-5N/A-6N/A3/31/20191-7N/A-6N/A12/31/20180-8N/A-7N/A9/30/20180-8N/A-7N/A6/30/20180-8N/A-8N/A3/31/20180-8N/A-7N/A12/31/20170-8N/A-7N/A12/31/20160-12N/A-3N/A12/31/20150-4N/A-4N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: IBXX.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: IBXX.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: IBXX.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: IBXX.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: IBXX.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: IBXX.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 10:20終値2026/06/04 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Imagion Biosystems Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 02Imagion Biosystems Ind Application for Magsense Phase 2 Clinical Trial Clears Fda ReviewImagion Biosystems Ltd. announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND) application, issuing a “Study May Proceed” letter for Phase 1b/2 clinical trials of the MagSense Imaging Agent in HER2+ breast cancer. MagSense is a first-of-its-class molecular MRI (mMRI) imaging agent that uses non-radioactive, bio-safe nanoparticles to help clinicians detect cancer earlier and with greater precision. Phase 1b/2 will be a combined trial designed to confirm the safety profile (Phase 1b) and evaluate efficacy in detecting nodal metastases (Phase 2) in patients with HER2+ breast cancer. Dr. Mohammad Eghtedari, section chief of Women's Imaging at City of Hope Cancer Center in Los Angeles, will serve as the trial’s principal investigator (PI). Eghtedari previously participated as an independent reviewer of MagSense in the company’s Phase I trial. The company expects the trial to yield insights into the potential impact on cost of care, patient outcomes, and clinical value. Paired with quantitative imaging techniques, the trial may produce critical training data for AI diagnostic tools. Conventional imaging can identify regions of interest using anatomical or morphological features, but without molecular specificity, cannot reliably differentiate benign from malignant tumors. MagSense uses targeted nanoparticles to increase imaging specificity, making it easier for clinicians to make diagnoses with certainty. The platform technology’s applications extend beyond breast cancer—Imagion has conducted pre-clinical studies of two additional imaging agents that target prostate and ovarian cancers, which will be prepared for IND-enabling studies.
お知らせ • Apr 07Imagion Biosystems Limited, Annual General Meeting, May 26, 2026Imagion Biosystems Limited, Annual General Meeting, May 26, 2026.
お知らせ • Feb 04Imagion Biosystems Ltd. Lodges IND with FDA for Phase 2 Trial of MagSense HER2 Targeting Imaging AgentImagion Biosystems Ltd. announced that the company has progressed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its MagSense®? targeted imaging agent. Following FDA approval, the company expects to start a Phase 2 clinical trial with the imaging agent for the detection of nodal metastases in HER2+ breast cancer patients. MagSense®? is a first-of-its-class molecular MRI (mMRI) platform technology that uses iron oxide nanoparticles with custom moieties (e.g., antibodies) to target specific disease biomarkers. Unlike general purpose contrast agents, MagSense®? particles are only detected when and where cancer is present. Using MRI, the presence of iron oxide produces a significant, identifiable change in image contrast, empowering clinicians with better information for diagnosis and treatment planning. Based on historical FDA review timelines, the company anticipates enrollment for the Phase 2 trial could begin as early as first quarter 2026. The company has selected and engaged all required strategic trial partners to manage the study and has begun the process of clinical study site engagement and progressing study logistics in compliance with Good Clinical Practices.
お知らせ • Sep 01Imagion Biosystems Limited Appoints Nina Webster as Non- Executive Director, Effective 1 September 2025Imagion Biosystems Limited announced the appointment of Dr. Nina Webster as a Non-Executive Director to the Board, effective 1 September 2025. Dr. Webster brings to the Board a wealth of experience in the Australian ASX listed pharmaceutical industry, holding leadership roles over a thirty-year period. She currently serves as Managing Director and Chief Executive Officer of Dimerix Ltd. Formerly the Commercial Director for Acrux Limited and Director of Commercialisation and Intellectual Property for Immuron Limited, Nina brings to IBX vast experience in investor relations, strategic planning, and scientific and operational execution. Dr. Webster holds a Ph.D in Pharmaceutics, a Bachelor's degree in Pharmacology, a Master's degree in Intellectual Property Law and an Executive MBA and currently also serves as Non-Executive Chairperson for SYNthesis BioVentures and as Non-Executive Director for Linear Clinical Research Limited. The addition of Dr. Webster to the IBX Board of Directors will further strengthen the Board's capabilities as the Company continues to execute on its strategic objectives to develop and gain regulatory approval for its pipeline of MagSense® molecular imaging technologies.
お知らせ • Aug 04Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 223,333,333 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Apr 01Imagion Biosystems Limited, Annual General Meeting, May 30, 2025Imagion Biosystems Limited, Annual General Meeting, May 30, 2025.
お知らせ • Dec 13Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million.Imagion Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 0.125 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Nov 08Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 0.125 million.Imagion Biosystems Limited has filed a Follow-on Equity Offering in the amount of AUD 0.125 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,250,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Aug 01Imagion Biosystems Limited Announces Board ChangesImagion Biosystems Limited announced that Ms Melanie Leydin will join the Board as a Non-Executive Director with the appointment effective from 31 July 2024. Ms Leydin has over 25 years' experience in the accounting profession and over 15 years as a company secretary with extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, re-organization of Companies and shareholder relations. IBX announced that, effective immediately before the conclusion of the General Meeting scheduled on 22 August 2024, Michael Harsh, David Ludvigson and Mark Van Astan, will cease to hold office. (That is, all of the directors who were in office at the time the directors' report (as included in the Company's annual financial report for the financial year ended 31 December 2023) was approved, other than Robert Proulx who acts as Executive Chairman and Managing Director, will cease to hold office).
お知らせ • May 06Imagion Biosystems Limited, Annual General Meeting, May 31, 2024Imagion Biosystems Limited, Annual General Meeting, May 31, 2024, at 10:01 E. Australia Standard Time. Location: K&L Gates Melbourne, Level 25, 525 Collins Street Melbourne Victoria Australia Agenda: To receive and consider the Financial Report of the Company and its controlled entities and the related Directors' and Auditor's Reports in respect of the financial year ended 31 December 2023; to consider adoption of the Remuneration Report; to approve re-Election of Director; and to consider other matters.
お知らせ • Jan 15+ 1 more updateImagion Biosystems Limited Announces Departure of Isaac Bright as CEOImagion Biosystems Limited informed the market that CEO, MD has resigned to pursue other opportunities effective January 15th, 2024.
お知らせ • Nov 15Imagion Biosystems Limited Approves Election of Isaac Bright as DirectorImagion Biosystems Limited announced that at its Extraordinary General Meeting held on 13 November 2023, the shareholders approved Election of Director - Dr. Isaac Bright.
お知らせ • Jul 17+ 1 more updateImagion Biosystems Limited Appoints Robert Proulx as Non-Executive ChairmanImagion Biosystems Limited announced that Robert Proulx is transitioning from his roles as President and CEO, and will be staying on as Non-Executive Chairman of the Board. This completes the leadership restructuring plan announced on 28 April 2023, which initiated the process to separate the role of the Chair from the role of CEO. To effect his transition to Non-Executive Chairman, the Company and Mr. Proulx by way of mutual consent ceased Mr. Proulx's employment under his previous roles, effective 20 June 2023. Mr. Proulx is assisting the incoming CEO, Dr Isaac Bright, from 20 June 2023 to 31 July 2023 to allow for a streamlined transition period for the Company. During this handover period (finishing on 31 July 2023), Mr. Proulx will receive a total payment commensurate to 60% of the base salary as specified in his most recent employment agreement (and as outlined in the annexure to this announcement). From 1 August 2023 Mr. Proulx will revert to a Chairman's fee of $63,000 per annum. Mr. Proulx commenced as Non-Executive Chairman on 20 June 2023. The key terms of his From the period of 20 June 2023 to 31 July 2023, Mr. Proulx will be paid at a rate of 60% of his base annual salary as specified in his most recent employment agreement (which equates to an annualized salary of $192,000 being 60% of $320,000). Mr. Proulx's appointment as Non-Executive Chairman of the Board may be terminated at any me in accordance with the provisions of the Company Constitution or the provisions of any applicable law. On any termination, no fee will be payable to Mr. Proulx in respect of any unexpired on of the term of his appointment.
お知らせ • Jun 19Imagion Biosystems Limited Announces CEO ChangesImagion Biosystems Limited announced it has appointed Isaac Bright, MD as CEO, effective 20 June 2023. Dr. Bright is a results-focused business leader and brings to Imagion over 20 years of experience as a health industry executive and venture capitalist in medical technology, biopharmaceuticals, and oncology-based molecular diagnostics. Dr. Bright most recently served as Co-Founder, CEO, and Chairman of RubrYc Therapeutics Inc. before its trade sale to iBio Inc. in September 2022. Prior to launching RubrYc, Dr. Bright was Chief Business Officer for molecular diagnostics innovator HealthTell Inc., driving its trade sale to iCarbonX, concomitant with RubrYc’s launch in 2018. Prior to that, Dr. Bright served as VP, Corporate Development for Synthetic Biologics Inc. and consulting Chief Business Officer for synthetic biology innovator musebio Inc. (currently Incripta Inc.) as it secured its $23 million Series B Preferred financing. Dr. Bright was the first American Partner investing with Merieux Developpement (currently, Merieux Equity Partners) from 2012 through 2016, during which he helped the firm raise €150 million Merieux Participations 2 fund. With Merieux, Dr. Bright led investments and Board representation for Imaginab Inc., Kalila Medical Inc. until its acquisition by Abbott, and Twist Bioscience before its IPO. Dr. Bright’s startup experience began as he built and led QuantaLife Inc.’s Corporate Development and Molecular Diagnostics functions from 2009-2011, leading to QuantaLife’s acquisition by Bio-Rad Laboratories Inc. Previously, Dr. Bright served as Sr. Associate, Corporate Development and Director, Business Development - Neuromodulation for global medtech leader Medtronic. Dr. Bright earned his bachelor’s degree in biochemistry from Pepperdine University, his medical degree from the Stanford University School of Medicine and was a Howard E. Mitchell Fellow earning his MBA from the Wharton School at the University of Pennsylvania. The hiring of Dr. Bright follows from the recent announcement on 28 April 2023 regarding the plan for Bob Proulx to retire from the role of CEO, remaining as Chairman of the Board.